COLD CHAIN, HOT TOPIC: The Challenge and Opportunity of Distributing Temperature-Sensitive Biopharmaceuticals and Cell Therapies

RACHEL GRIFFITHS | December 20, 2016

article image
Pharmaceutical industry interest in biopharmaceuticals, cell therapies and, more recently, biosimilars has increased significantly1,2. In addition to targeting and treating disease more effectively than small molecule medicines, such products have the potential to generate higher revenues and are less likely to face competition when they go off patent3,4. However, unlike small molecule drugs, which can be easily transported, large molecule biopharmaceuticals are highly sensitive to temperature fluctuations and require special handling5. Large molecule drugs are also more expensive to develop and manufacture than small molecule products, which means any lost as a result of problems during transportation have a higher financial impact6. Similarly, transporting cell therapies is a challenge7. While hydrogelbased alternative technologies are being developed, the vast majority of cell therapies are still shipped as frozen stocks8.

Spotlight

Invent Farma

Invent Farma is a pharmaceutical group that develops, manufactures and markets active pharmaceutical ingredients (API) and pharmaceuticals specialties. Invent Farma forms the Spanish part of the NuPharm Group, a strategic combination of successful companies with the shared vision to be the European leader in pharmaceutical products for the Central Nervous System (CNS).

OTHER ARTICLES

What to Watch in 2020: Non-Specialty Drugs

Article | March 1, 2020

Pharmaceutical manufacturers are constantly working to develop new and improved medications. Join us as we explore the non-specialty drugs you should be watching in 2020. If you missed last week’s article about the most important upcoming specialty drugs, be sure to check it out here. Approximately 40 new medications are approved by the Food and Drug Administration (FDA) every year.1 (Please note: If you’re curious about what it takes to develop a drug and bring it to market, check out our previous article). Why should you care about these new medications? Because they can affect both your organization’s pharmacy spend and your members’ cost share. For non-specialty drugs, we will focus on medications that may come to market this year, including ones that are currently being reviewed by the FDA, or that are in the last clinical trial (Phase III) stage.

Read More

The Future of Pharma Beyond Blockbusters

Article | March 1, 2020

We’ve all heard the saying “treat the patient, not the disease”, and this couldn’t be truer in today’s ever-changing pharmaceutical landscape. We are living in a time of revolution – advancements in genomics and technology are improving our ability to develop precise drugs and targeted therapies, rather than focusing on a one size fits all approach. Each individual’s genetic makeup is slightly different from everyone else’s,

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | March 1, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Top Pharmaceutical Firms Urge FDA to Adopt Blockchain for Drug Tracking

Article | March 1, 2020

Leading market participants in the United States pharmaceutical industry, logistics firms, distributors and other stakeholders in the pharma supply chain have come together to publish a report buttressing the need for industry players to adopt blockchain for tracking prescription drugs, following the successful completion of a DLT pilot project with the Food and Drug Administration (FDA), according to reports on February 24, 2020. Though nascent, blockchain technology, the building blocks of Bitcoin (BTC) and other cryptocurrencies are fast gaining ground across various ecosystems, due to its immutability, security, privacy, and other intricate properties. In the latest development, 25 leading manufacturers of pharmaceutical products, logistics partners and other market participants in the pharma supply chain, have published a report that highlights the importance of blockchain technology in drug traceability.

Read More

Spotlight

Invent Farma

Invent Farma is a pharmaceutical group that develops, manufactures and markets active pharmaceutical ingredients (API) and pharmaceuticals specialties. Invent Farma forms the Spanish part of the NuPharm Group, a strategic combination of successful companies with the shared vision to be the European leader in pharmaceutical products for the Central Nervous System (CNS).

Events